Chronic Management of Myasthenia Gravis
Begin with pyridostigmine 30 mg orally three times daily as first-line chronic therapy, titrating up to a maximum of 120 mg four times daily based on symptom response, and add corticosteroids (prednisone 1–1.5 mg/kg daily) combined with azathioprine as steroid-sparing immunosuppression for patients requiring disease control beyond symptomatic treatment. 1, 2, 3
First-Line Symptomatic Treatment
Pyridostigmine (acetylcholinesterase inhibitor) is the cornerstone of initial chronic management, starting at 30 mg orally three times daily and gradually increasing to a maximum of 120 mg orally four times daily as tolerated based on clinical response. 4, 1, 5, 6, 2, 3
Approximately 50% of patients with ocular myasthenia show minimal response to pyridostigmine alone, which does not exclude the diagnosis and warrants escalation to immunosuppressive therapy. 1, 6
Ambenonium and beta-adrenergic agonists serve as second-line symptomatic options when pyridostigmine is insufficient or not tolerated. 2
Immunosuppressive Therapy Algorithm
Mild to Moderate Disease (MGFA Class I–II)
Add corticosteroids (prednisone 1–1.5 mg/kg orally daily) if pyridostigmine provides inadequate symptom control, with 66–85% of patients showing positive response. 1, 6, 7
Combine corticosteroids at the lowest effective dose with azathioprine as first-line immunosuppression to achieve steroid-sparing effect and long-term disease control. 2, 3, 7
Rituximab represents an alternative first-line immunosuppressive option, particularly effective in MuSK-antibody-positive patients. 2, 3, 7
Taper corticosteroids gradually based on symptom improvement once disease control is achieved. 4, 1, 5
Moderate to Severe Disease (MGFA Class III–IV)
For highly active generalized MG with AChR-antibody-positive status, add complement inhibitors (eculizumab, ravulizumab, or zilucoplan) or FcRn modulators (efgartigimod, rozanolixizumab, or nipocalimab) as add-on therapy to conventional immunosuppression. 7, 8, 9
For MuSK-antibody-positive patients with highly active disease, rituximab is specifically recommended over complement inhibitors. 7
Mycophenolate, methotrexate, and tacrolimus serve as second-line steroid-sparing immunosuppressants when azathioprine is contraindicated or ineffective. 2, 3, 7
Thymectomy Considerations
Perform thymectomy in all patients with thymoma-associated MG regardless of age. 2, 3, 7
Offer thymectomy to non-thymoma patients with AChR-antibody-positive generalized MG up to age 50–65 years who do not achieve remission on symptomatic treatment alone, as evidence from the MGTX trial demonstrates clear benefit. 2, 3, 10
Recognize that clinical improvement after thymectomy may take months to years, requiring continued immunosuppressive therapy during this latency period. 8
Novel Biologics: Specific Indications
FcRn Inhibitors
Efgartigimod is approved for AChR-antibody-positive generalized MG and demonstrates significant improvement in MG-ADL scores. 7, 8, 9
Rozanolixizumab and nipocalimab are uniquely approved for both AChR- and MuSK-antibody-positive MG, offering broader applicability. 9
These agents provide rapid onset of action (within weeks) compared to traditional immunosuppressants. 8, 9
Complement Inhibitors
Eculizumab, ravulizumab, and zilucoplan are indicated for refractory AChR-antibody-positive generalized MG as add-on therapy. 7, 8, 9
Zilucoplan offers the advantage of subcutaneous self-administration, improving patient convenience. 9
All patients receiving complement inhibitors must be vaccinated against Neisseria meningitidis at least 2 weeks before treatment initiation to prevent life-threatening meningococcal infection. 9
Critical Medications to Avoid
Strictly avoid the following medications that exacerbate myasthenic symptoms through interference with neuromuscular transmission: 4, 1, 5
β-blockers (worsen neuromuscular transmission)
Intravenous magnesium (blocks presynaptic calcium channels)
Fluoroquinolone antibiotics (aminoglycosides, macrolides)
Aminoglycoside antibiotics
Macrolide antibiotics
Metoclopramide (can trigger myasthenic crisis)
Statins warrant careful consideration: while associated with short-term increased risk of ICU admission for MG exacerbation (HR 1.133), they demonstrate significant long-term mortality benefit (HR 0.626), suggesting cardiovascular benefits outweigh myasthenic risks in appropriate patients. 11
Monitoring Requirements
Perform pulmonary function testing with negative inspiratory force (NIF) and vital capacity (VC) at baseline and regularly during follow-up, especially in patients with bulbar symptoms or generalized weakness, as dysphagia and bulbar weakness precede myasthenic crisis in >50% of cases. 4, 1, 5
Check troponin, ECG, and consider echocardiography if respiratory insufficiency or elevated creatine kinase is present to exclude concurrent myocarditis. 4, 1
Monitor disease activity using validated MG-specific scores (MG-ADL, QMG, MGFA classification) to guide treatment escalation decisions. 7
Obtain neurology consultation for all patients to ensure appropriate long-term specialized follow-up and treatment adjustments. 4, 1, 5
Special Populations
Ocular Myasthenia Gravis (MGFA Class I)
Initiate early corticosteroid treatment when ocular motility abnormalities persist despite pyridostigmine, as 50–80% of patients with isolated ocular symptoms progress to generalized MG within 2 years. 1, 10
Consider thymectomy in AChR-antibody-positive ocular MG patients under age 50–65 who fail symptomatic treatment. 3, 7
Pregnancy Planning
Plan pregnancies with optimal treatment adjustment, recognizing that azathioprine carries teratogenic risk and requires substitution with safer alternatives. 2, 10
Provide information about neonatal MG risk and ensure multidisciplinary obstetric and neonatal care. 2
Elderly Patients
Adjust immunosuppressive regimens based on comorbidities, recognizing that corticosteroid side effects may be more pronounced. 10
Consider novel biologics earlier in elderly patients to minimize cumulative steroid exposure. 8
Acute Exacerbations and Crisis Management
For Grade 3–4 exacerbations or myasthenic crisis, immediately hospitalize with ICU-level monitoring and initiate IVIG (2 g/kg over 5 days) or plasmapheresis (5 sessions) in addition to continuing corticosteroids. 4, 1, 5, 6
Permanently discontinue immune checkpoint inhibitors if MG develops in the oncology setting, as ICPi-associated MG may be monophasic but carries high risk of progression. 4
Perform daily neurologic evaluation and frequent pulmonary function assessment during acute exacerbations. 4, 1, 5
Rehabilitation and Functional Recovery
Initiate aggressive physical and occupational therapy as soon as symptoms are adequately controlled, as systematic physical training safely improves muscle strength, daily function, and quality of life. 5
Plan return to sedentary or light-duty work within 2–4 weeks after achieving minimal manifestations (MGFA Class I or less). 5
Resume basic activities of daily living (bathing, dressing) within 1–2 weeks of symptom control, scheduling activities during peak anticholinesterase effect. 5
Allow driving resumption once stable at Grade 1 or less (generally 1–2 weeks after good control), provided no diplopia or significant limb weakness persists. 5
Treatment Goals and Long-Term Strategy
The central treatment goal is rapid achievement of complete disease control, defined as minimal manifestations or pharmacologic remission. 7
Most patients require lifelong immunosuppressive therapy, as MG is a chronic condition that can be improved but not cured with current treatments. 8
Regular long-term specialized follow-up is essential due to spontaneous disease fluctuations, comorbidities, and changes in life conditions. 2
Address psychological factors (depression, anxiety, patient expectations) proactively, as these markedly influence functional recovery and treatment adherence. 5